title: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome.
abstract: P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P=0.024, 0.014, 0.006, respectively, chi(2)-test or Fisher's exact test). We also found significantly higher (P=0.019, chi(2)-test) T allele frequency in breast cancer patients (n=221) than in controls (n=113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n=38; P=0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n=102; P=0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, P. J. Safarik University, Kosice, Slovak Republic.
authors.forename: M
authors.initials: M
authors.lastname: Cizmarikova
authors.forename: M
authors.initials: M
authors.lastname: Wagnerova
authors.forename: L
authors.initials: L
authors.lastname: Schonova
authors.forename: V
authors.initials: V
authors.lastname: Habalova
authors.forename: A
authors.initials: A
authors.lastname: Kohut
authors.forename: A
authors.initials: A
authors.lastname: Linkova
authors.forename: M
authors.initials: M
authors.lastname: Sarissky
authors.forename: J
authors.initials: J
authors.lastname: Mojzis
authors.forename: L
authors.initials: L
authors.lastname: Mirossay
authors.forename: A
authors.initials: A
authors.lastname: Mirossay
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005787:Gene Frequency; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018943:Anthracyclines